A Study of Canakinumab With Chemotherapy, Radiation Therapy, and Durvalumab in People With Lung Cancer
The researchers are doing this study to find out whether canakinumab in combination with chemoradiation and durvalumab is an effective and safe treatment for people with locally advanced non-small cell lung cancer (NSCLC).
Non-small Cell Lung Cancer
DRUG: Canakinumab|DRUG: Durvalumab|RADIATION: Radiation therapy|DRUG: Chemotherapy
progression-free survival, 2 years
Rate of grade â‰¥ 2 pneumonitis, by CTCAE v. 5.0, 2 years
The researchers are doing this study to find out whether canakinumab in combination with chemoradiation and durvalumab is an effective and safe treatment for people with locally advanced non-small cell lung cancer (NSCLC).